US FDA advisory panels to drop vote on approvability in favour of benefit:risk
This article was originally published in RAJ Devices
The US Food and Drug Administration is to change to the way its medical device advisory committees discuss data and information during public hearings on products under review for premarket approval (PMA). The change will apply from 1 May1,2.
You may also be interested in...
As companies undergo pharmacovigilance inspections from a growing multitude of regulatory authorities from around the globe, a senior pharmaceutical industry executive discusses how her company has been handling this complex and challenging task.
While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.
The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.